GSK plc (NYSE:GSK) Stake Increased by Lincluden Management Ltd.

Lincluden Management Ltd. increased its stake in GSK plc (NYSE:GSK) by 1.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 66,001 shares of the pharmaceutical company’s stock after buying an additional 833 shares during the period. Lincluden Management Ltd.’s holdings in GSK were worth $2,698,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in GSK. Primecap Management Co. CA increased its stake in shares of GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock worth $558,689,000 after buying an additional 1,773,020 shares during the last quarter. Mondrian Investment Partners LTD increased its stake in GSK by 37.8% during the first quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after purchasing an additional 1,512,442 shares during the last quarter. Acadian Asset Management LLC increased its stake in GSK by 180.0% during the first quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock valued at $95,129,000 after purchasing an additional 1,426,935 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in GSK during the second quarter valued at $52,487,000. Finally, Kahn Brothers Group Inc. bought a new stake in GSK during the first quarter valued at $53,743,000. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 0.7 %

Shares of GSK stock opened at $36.74 on Friday. The business’s 50 day moving average is $40.78 and its two-hundred day moving average is $41.05. The company has a market cap of $76.15 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.65. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. GSK plc has a 12 month low of $33.67 and a 12 month high of $45.92.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 7.97% and a return on equity of 51.23%. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. Equities analysts predict that GSK plc will post 4.08 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. The ex-dividend date is Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.28%. GSK’s dividend payout ratio (DPR) is presently 100.00%.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the business’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 10.00% of the company’s stock.

Analysts Set New Price Targets

GSK has been the subject of several recent research reports. Argus upgraded shares of GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday. Finally, Barclays upgraded shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.